Radical Minimally Invasive Surgery After Immuno-chemotherapy in Initially-unresectable Stage IIIB Non-small cell Lung Cancer
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Surgery
Reference10 articles.
1. Brief report: three-year overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC - Update from PACIFIC;Gray;J Thorac Oncol,2019
2. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial;Provencio;Lancet Oncol,2020
3. Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): interim analysis and biomarker data from a multicenter study (LCMC3);Kwiatkowski;J Clin Oncol,2019
4. Sleeve lobectomy after neoadjuvant chemoimmunotherapy/chemotherapy for local advanced non-small cell lung cancer;Liang;Transl Lung Cancer Res,2021
5. Safety and feasibility of lung resection after immunotherapy for metastatic or unresectable tumors;Bott;Ann Thorac Surg,2018
Cited by 29 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. A survey on puncture models and path planning algorithms of bevel-tipped flexible needles;Heliyon;2024-02
2. Efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy in potentially resectable stage IIIA/IIIB non-small cell lung cancer: Neo-Pre-IC, a single-arm phase 2 trial;eClinicalMedicine;2024-02
3. Surgery Challenges and Postoperative Complications of Lung Cancer after Neoadjuvant Immunotherapy: A Cohort Study;2023-12-07
4. Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials;Critical Reviews in Oncology/Hematology;2023-12
5. Conversion therapy with immunotherapy plus chemotherapy achieves a pathological complete response in stage IIIC NSCLC;Frontiers in Immunology;2023-11-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"全球学者库"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前全球学者库共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2023 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3